#273: Is Novo Nordisk a Buy? An Undervalued Stock or Falling Knife?
Novo Nordisk faced another tough earnings season, with the stock falling 30% after it revised its growth guidance due to increased competition from Eli Lilly and the (now-illegal) compounders. This has brought the stock down to a tantalizing 12x earnings. Is this a great time to pick up shares, or are investors…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Stock Club
See all episodes →Chapters Group: Europe's Mini Constellation Software With Compounding Quality's Pieter Slegers
Ouster & Schaeffler: Two More Investicon Stock Picks, One Year Later | Stock Club 323
Two Overlooked AI Stocks Worth Knowing About
Similar episodes from other shows
More like Stock Club →
A New Name in Weight-Loss Drugs
Betting on OpenAI, SpaceX Dust Settles, Josh’s New Trade
Can a GLP-1 Pill Revive Novo Nordisk?
Novo Nordisk, Eli Lilly and the GLP-1 economy
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.